Reduced intensity preparative regimens are increasingly used for conditioning prior to allogeneic stem cell transplantation. As opposed to classical methods of pretransplant conditioning, patients receive predominantly immunosuppressive therapies that facilitate early engraftment, while cells within the graft itself promote continuation of the engraftment process. Despite early hopes that this form of transplant would be devoid of grade III and IV acute toxicities, there is a substantial amount of shortterm morbidity associated with the technique. Although long-term follow-up is not yet available, it is hoped that these regimens will spare young patients many of the late effects (cataracts, growth retardation, endocrine and reproductive problems) that are often associated with classical pre-transplant conditioning regimens. Reliable engraftment and leukemic control have been demonstrated in a large number of both adult and pediatric transplant recipients of these regimens, many of whom were deemed at high risk for standard conditioning because of serious co-morbidities, previous autologous transplantation or multiply relapsed disease. A brief review of the state of the art of this technology as it applies to pediatric transplantation is presented. Preliminary results of a survey of pediatric transplant centers indicate that a variety of protocols are used for a variety of indications. The use of standardized criteria for implementation of reduced intensity preparative regimens, the use of a limited number of regimens, and more extensive data collection will permit the elaboration of prospective comparative studies of this new and exciting modality. Bone Marrow Transplantation (2005) 35, S39-S43.
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Although the term 'reduced-intensity transplant' is fairly new, we have actually been performing such transplants for many years, and several lines of evidence have suggested that aggressive pre-transplant conditioning could be safely replaced by milder and less toxic regimens without compromising outcome in terms of successful engraftment and in terms of relapse-free survival in patients transplanted for treatment of malignant and nonmalignant diseases. Patients with Fanconi's anemia (FA), 1 who poorly tolerate aggressive preparative regimens, have been successfully transplanted with low-dose cyclophosphamide and reduced-dose radiation therapy (although low doses of radiation and alkylating agents may be pharmacodynamically equivalent in these patients to standard doses of the same agents in non-FA patients). Patients with severe aplastic anemia enjoy full donor engraftment following immunosuppressive conditioning only (cyclophosphamide with or without antithymocyte globulin). 2 Patients with severe combined immune deficiency routinely experience lymphoid engraftment in the absence of any form of pretransplant conditioning, 3 and full trilineage hematopoietic engraftment has been reported in such transplants. 4 The ability of the graft to eliminate residual malignant cells in the patient independent of the effects of pre-transplant conditioning has long been inferred from the increased leukemia-free survival rates in patients who received reduced graft-versus-host-disease prophylaxis after stemcell transplantation. More compelling evidence of the graftversus-leukemia effect was provided by the dramatic effect of donor lymphocyte infusions in patients with posttransplantation recurrences of chronic myelogenous leukemia (CML). 5 These observations have prompted the development of a veritable alphabet soup of reducedintensity conditioning regimens for use in patients with a variety of diseases.
The minimal requirements for pre-transplant conditioning could be defined as follows: pre-transplant conditioning must provide sufficient immune suppression to prevent the immediate rejection of the donor's primitive hematopoietic precursors, while donor lymphocytes (either contained in the graft at the time of transplant or subsequently elaborated by the graft after transplant) provide the antitumor effect that maintains (or in some cases, induces) disease remission and create a hospitable environment for longterm donor-derived hematopoiesis. RIT regimens are defined by their lack of toxicity for primitive host-derived hematopoiesis; autologous recovery of hematopoiesis would be expected to occur within 1 month in the absence of donor-cell infusion. Many of the patients treated with RIT protocols to date have been selected for their inability to tolerate fully myeloablative conditioning because of various co-morbidities or advanced age, although children have been included in some series. RIT regimens vary in their intensity, with some causing little or no myelosuppression, and others inducing a greater degree of this complication. As RIT regimens are often 'institution-specific', it is difficult to draw firm conclusions regarding the applicability of a specific program to a specific type of patient.
How does donor engraftment occur following RIT?
Prior to the advent of RIT, transplant dogma stipulated that host hematopoiesis must be erased by chemoradiotherapy prior to the infusion of donor cells. The efficacy of RIT, however, calls into question the hypothesis that pretransplant conditioning is required to create 'space' for engrafting cells within the marrow cavity. 6 Additionally, donor and host cells can coexist in the same marrow space without sacrificing the success of transplant (particularly in patients with nonmalignant disease); indeed, a state of stable mixed chimerism in these patients may reduce the rate of severe graft-versus-host disease. 7, 8 In all likelihood, donor cells gain the upper hand following RIT using 'veto' capabilities. 9 Veto cells, which include certain T-cell subsets and CD34 þ cells, eliminate host cells capable of mounting a host-versus-graft reaction, tilting the battle for immune predominance in favor of the grafted cells. [10] [11] [12] Functional veto cells infused with the graft probably exert their effects in the hours and days immediately following stem cell infusion.
The hope and the reality of RIT in children: is less really better?
Patients, their families, and their physicians dread the short-and long-term toxicities of conventional stem cell transplantation. In young patients, high doses of alkylating agents and radiation pose specific hazards in terms of future linear growth, intellectual development, and fertility. 13 Patients in Third-World countries may also be denied stem-cell transplantation because of the lack of the specialized facilities needed to care for patients in the initial post-transplant period. 14, 15 RIT should theoretically provide a solution to all these issues. RIT can often be performed on an outpatient basis, should have a minimal effect on growth potential or fertility, and should induce fewer serious side effects on specific organs. It should also be cheaper and simpler to perform than standard transplantation, as it requires less hospitalization time and fewer transfusions. The sickest patients should be able to weather the tribulations of minimally intensive conditioning.
Unfortunately, the toxicity of RIT regimens has been found to be somewhat greater than originally expected. Del Tore et al 16 17 The delayed onset of severe infections after RIT also increased the overall costs of the procedure, despite the initially lower inpatient costs compared to myeloablative transplants. 18 The 100-day mortality associated with RIT vary according to underlying disease, co-morbid conditions, and the specific RIT regimen employed, and hovers around 25% in many series. However, this number needs to be understood in the context of the high-risk population that is usually selected for this type of procedure. 19 The long-term effects of RIT on reproductive or endocrine function remain unclear, and longer follow-up is needed to reach reliable conclusions. A case in point is the unknown effect of lower doses of busulfan on the developing gonads of children.
Does RIT work?
RIT works. Although most of the relevant studies so far come from single transplant centers, and although the list of protocols in current use is confusingly long, it is clear that long-term engraftment is achieved in most patients undergoing RIT. Patients exposed to standard-dose chemotherapy before the transplant procedure show faster myeloid and T-cell engraftment after RIT than chemotherapy-naive patients, 20 although good engraftment has also been reported after RIT in some patients with nonmalignant diseases. 21 RIT regimens run the gamut from predominantly immunosuppressive (very low dose total-body irradiation and fludarabine) to myelotoxic (regimens containing substantial doses of cyclophosphamide or melphalan). Fludarabine is used in most RIT regimens, although pentostatin has also been associated with good results. 22 The addition of fludarabine to an immunosuppressive regimen of low-dose total body irradiation, coupled with post-transplant cyclosporine and mycophenolate mofetil, results in high rates of engraftment. 23 RIT regimens tend to be named for their city of origin. The most widely used ones are listed below.
Jerusalem protocol: fludarabine, Fresenius
s antithymocyte globulin, and 'minimal' cytotoxic therapy (either busulfan 8 mg/kg or cyclophosphamide 120 mg/kg). 25 
MD Anderson protocol (and its variations):
fludarabine combined with Ara-C, melphalan, and cyclophosphamide or an anthracycline. 26 It is reasonable to assume that patients with aggressive malignancies should received some form of cytotoxic conditioning to permit disease control during the initial post-transplant period, before the graft-versus-malignancy reaction is fully manifest. By contrast, patients with indolent malignancies might fare just as well with milder conditioning to permit donor engraftment and subsequent elaboration of the graft-versus-malignancy reaction, without the need for cytotoxic bridging therapy. As an example, the MD Anderson lymphoma protocol stipulates that patients with aggressive lymphoma receive a more cytotoxic preparative RIT regimen than those with indolent forms of the disease. 27 Purely immunosuppressive regimens may be insufficient for durable engraftment in recipients with robust pretransplant immunity, 28 while inducing durable trilineage hematopoietic engraftment in immune compromised patients with hematological malignancies. 24 
Source of stem cells
Most RIT regimens utilize HLA-matched sibling donors, although a few series included unrelated HLA-matched donors. High-dose stem cell infusions (410 Â 10 6 /kg CD 34 þ cells/kg) have been reported, 29 but more conventional doses of stem cells from either the peripheral blood or marrow are sufficient for both engraftment and graftversus-leukemia effects under most circumstances. 20, 24 The rather surprising success of RIT with the low doses of stem cells derived from umbilical cord blood from unrelated donors suggests that this stem cell source deserves further evaluation in the RIT context, particularly in small children. 30, 31 Formal comparisons of bone-marrow-and peripheral-blood-derived stem cells in patients undergoing RIT have not been reported.
Diseases treated with RIT
The list of diseases treated with RIT covers the range of diseases for which stem cell transplant is effective. Most reports of RIT involve predominantly adult patients, although several series of pediatric RIT protocols have been reported.
RIT regimens can induce complete remission in patients with acute and chronic leukemia who have measurable disease at the time of transplant. 24 However, specific data on RIT in children with refractory leukemia are not available. Objective responses to allogeneic RIT transplantation have also been observed in patients with metastatic solid tumors. 32 The number of children with solid tumors treated with RIT protocols is still too small to yield conclusions as to the efficacy of this modality in pediatric practice. Six teenagers with Hodgkin's disease from a single institution were treated with diverse fludarabine-based RIT regimens. Although event-free survival was poor, there were three long-term survivors (two after the addition of various other therapies). 33 A variety of nonmalignant diseases have also been successfully treated using RIT regimens.
Monitoring engraftment after RIT
As trilineage engraftment following RIT is a protracted and often incomplete process (resulting in mixed hematopoietic chimerism that can vary in hematopoietic subpopulations), evaluation of the percentage of donor or recipient signals in a sample of whole blood may yield misleading results. In one study, fluorescence in situ hybridization (FISH) and analysis of short tandem repeats on leukocyte subfractions obtained by fluorescence-activated cell sorter (FACS) were used to prospectively evaluate engraftment in 39 children treated by an assortment of RIT protocols. Specific pretransplant conditioning regimens varied according to the patients' underlying disease, and some of the patients received T-celldepleted grafts. The authors found that the presence of recipient-derived natural killer (NK) cells 1 month after transplantation strongly predicted graft rejection (5/5 patients). By contrast, no episodes of graft rejection occurred in 24 patients with donor-derived NK cells at the same time point. Late graft rejection later occurred in 40% of the patients with mixed NK cells chimerism. Mixed T-cell donor/recipient chimerism was protective against severe graft-versus-host disease, but T-cell chimerism in this cohort may have been influenced by the large number of patients who received T-cell-depleted grafts. Serial evaluation of the extent of chimerism in different cellular subfractions proved to be an indispensable tool, because it enabled the judicious tapering of immunosuppression and the timely application of donor lymphocyte infusions. 34 
Donor lymphocyte infusions after RIT
Donor lymphocyte infusions are a potential adjuvant to RIT, to facilitate immune-mediated tumor cell destruction and to bolster engraftment in cases of mixed chimerism. In one multi-center series, an objective response (complete or partial) was documented in 25% of 48 patients who received donor lymphocyte infusions for the treatment of persistent, relapsed, or progressive disease following RIT; responses correlated with the occurrence of graft-versushost disease. 35 The association of disease response and graft-versus-host disease following donor lymphocyte infusions has been mentioned previously.
Where do we stand in 2004?
On behalf of the Pediatric Disease Working Party of the EBMT, we conducted a survey on the practice of pediatric RIT in 103 EBMT centers where pediatric stem cell transplants are performed. Responses were obtained from 24 centers (12 dedicated pediatric and 12 combined adult/ pediatric units). In all, 17 of the 24 centers used RIT, 80% of them exclusively in patients with relative contraindications for conventional transplantation. Acute leukemia, lymphoma, and myelodysplastic syndrome were the main indications for RIT. Most centers (10/17) used both matched-sibling and unrelated donors; only a few reported the use of unrelated cord blood (six) or a haploidentical donor (four).
Conditioning included fludarabine (17 centers), melphalan (nine centers) or busulfan (eight centers), combined with antithymocyte globulin (14 centers) or cyclosporine A (12 centers). Only three centers included radiotherapy as part of the reduced-intensity conditioning. The survey is ongoing, and a formal registry study should be started. Analysis of registry data will permit a more comprehensive analysis of RIT in children, free of the inherent bias seen in case series, where success in small cohorts can lead to premature optimism.
RIT is a new technology that promises to revolutionize the way in which stem cell transplantation is performed. It was initially expected to bestow the benefits of allogeneic transplantation with none of its dreaded side effects. Although our increasing experience has somewhat tempered the enthusiasm of the transplant community for this new modality, RIT still holds great promise. Multiinstitutional and group-wide prospective studies are urgently needed to define the optimal regimens and the optimal candidates. Monetary costs, short-and long-term side effects, and rates of disease control need to be carefully evaluated before RIT can replace conventional stem cell transplant regimens in children with malignant and nonmalignant diseases. The design of prospective studies in which standard and RIT are compared will pose formidable logistic and ethical challenges for investigators, as some patients would be randomized to receive highly toxic conditioning while others receive less toxic treatment on a semiambulatory basis. Patient recruitment might also be hampered by parental and physician bias as to the 'safest' treatment. Until these studies can be organized, implemented, and interpreted, the uniform use of a limited number of regimens according to disease-and patientspecific criteria coupled with organized data capture will permit retrospective case-matched comparison with patients undergoing standard stem cell transplantation, similar to that performed by Rocha et al 36 in the evaluation of umbilical cord blood transplantation in children with acute leukemia. We trust these findings will clarify the true place of RIT in the treatment of oncological and hematological diseases in children.
